



THE UNIVERSITY
of ADELAIDE

***In Vitro* Investigation Of Intracellular Ponatinib
Transport And Modeling Ponatinib Resistance In *BCR-
ABL1+* Cell Lines: Implications For Therapeutic
Strategies**

Liu Lu

Leukemia Research Unit
South Australian Health and Medical Research Institute (SAHMRI)
&
The Faculty of Health Sciences
School of Medicine
The University of Adelaide

Thesis submitted to the University of Adelaide in candidature
for the degree of Doctor of Philosophy 2015

Supervisors: Prof. Deborah White & Prof. Timothy Hughes

Table of contents

Table of contents	1
Declaration	10
Acknowledgements	11
Abstract	14
Abbreviations	17
Chapter 1 :	21
1.1 Chronic myeloid leukaemia	22
1.2 Philadelphia chromosome, Bcr-Abl oncoprotein and CML.....	22
1.3 Treatment.....	29
1.3.1 Stem cell therapy, interferon and hydroxyurea	29
1.3.2 Imatinib	30
1.4 Imatinib resistance and second generation TKIs.....	33
1.4.1 <i>BCR-ABL1</i> KD mutations.....	34
1.4.2 <i>BCR-ABL1</i> amplification.....	35
1.4.3 Drug efflux transporter mediated resistance.....	38
1.4.4 Drug influx transporter mediated resistance.....	39
1.4.5 Activation of alternative signalling pathways.....	40
1.5 Ponatinib.....	41
1.5.1 Ponatinib demonstrates efficacy against single KD mutations <i>in vitro</i> ..	46
1.5.2 Ponatinib in targeting compound mutation	47
1.5.3 Influx and efflux transporters of ponatinib.....	47

1.6 Hypothesis and aims.....	48
1.6.1 Hypothesis.....	48
1.6.2 Aims.....	48
Chapter 2 :	49
2.1 Commonly used reagents and buffer.....	50
2.2 Western blot antibodies.....	53
2.3 Solutions, buffers and media.....	54
2.3.1 Cell culture media.....	54
2.3.2 IMDM cell culture media	54
2.3.3 10% Foetal Calf Serum (FCS)	54
2.3.4 dNTP set (N=A, T, C, G).....	55
2.3.5 Flow cytometry fixative (FACS fix)	55
2.3.6 Flow Cytometry wash (FACS wash)	55
2.3.7 Freeze mix (cryoprotectant)	55
2.3.8 SDS-Polyacrylamide Gel	56
2.3.9 1×SDS-PAGE running buffer (pH 8.3).....	56
2.3.10 1×Tris Buffered Saline (TBS).....	57
2.3.11 1×Tris Buffered Saline with 0.1% Tween 20 (TBST).....	57
2.3.12 1×SDS-PAGE Transfer buffer (pH 8.3).....	57
2.3.13 1× Laemmli's Buffer (modified)	57
2.3.14 2.5% skim milk Western blocking solution.....	58
2.3.15 2.5% BSA Western blocking solution.....	58
2.3.16 Random Hexamer Primer	58

2.3.17	Tris Buffer A (pH 8.8)	58
2.3.18	Tris Buffer B (pH 6.8)	59
2.4	Tyrosine kinase inhibitors	59
2.4.1	imatinib (MW = 589.72)	59
2.4.2	nilotinib (MW = 529.5)	59
2.4.3	dasatinib (MW = 506.2)	59
2.4.4	Ponatinib (MW = 532.56)	60
2.5	Transporter inhibitors	60
2.5.1	Prazosin Hydrochloride	60
2.5.2	Cyclosporin A	60
2.5.3	Ko143	60
2.5.4	Pantoprazole	61
2.5.5	Ibuprofen	61
2.5.6	Procainamide	61
2.6	Axl inhibitors	61
2.6.1	R428	61
2.6.2	BMS-777607	62
2.7	Cell lines	62
2.7.1	Culture of TKI-naïve and TKI-resistant cell lines	62
2.8	General and specialised techniques	64
2.8.1	Cell counts and viability assessment	64
2.8.2	Cryopreservation of cells	64
2.8.3	Thawing cells	64

2.8.4	Viability assay	65
2.8.5	Ponatinib Intracellular Uptake and Retention assay (IUR).....	65
2.8.6	Antibody staining for Flow Cytometric Analysis	66
2.8.7	RNA extraction	66
2.8.8	cDNA synthesis.....	67
2.8.9	RQ-PCR:.....	67
2.8.10	AXL transcript quantitation	69
2.8.11	Sequencing the <i>BCR-ABL1</i> kinase domain	70
2.8.11.1	Long PCR.....	70
2.8.11.2	2% Agarose Gel	71
2.8.11.3	ExoSAP-IT purification	72
2.8.11.4	Sequencing reaction.....	72
2.8.12	SDS-PAGE and Western blot	72
2.8.12.1	Western blotting for proteins other than CrkL.....	73
2.8.12.2	Protein extraction using NP40 lysis buffer	74
2.8.13	DC assay measuring protein concentration	75
2.8.14	Lentiviral transfection and transduction	76
2.8.15	Statistical Analyses.....	77
Chapter 3	:	78
Chapter 4	:	91
4.1	Introduction	92
4.1.1	Bcr-Abl kinase domain mutations.....	92
4.1.2	<i>BCR-ABL1</i> overexpression	93

4.1.3	Generation TKI resistance and the <u>K562-T315I</u> cell line.....	94
4.2	Approach	95
4.2.1	Generation of ponatinib resistant cell lines	95
4.2.2	Analysis of ponatinib-resistant cell line <u>K562 T315I-R</u>	97
4.3	Results.....	97
4.3.1	<u>K562 T315I</u> cells cultured in 100 nM ponatinib demonstrate resistance to TKIs <i>in vitro</i>	97
4.3.2	No evidence of ABCB1 or ABCG2 up-regulation in the <u>K562 T315I-R</u> ponatinib resistant line.....	107
4.3.3	<u>K562 T315I-R</u> resistant line demonstrates further <i>BCR-ABL1</i> mRNA overexpression, together with increased total and phospho-Bcr-Abl protein	112
4.3.4	<u>K562 T315I-R</u> ponatinib resistant line demonstrates increased <i>BCR-ABL1</i> ^{T315I} mutation level.....	114
4.3.5	The percentage of T315I in cell lines corresponds to ponatinib sensitivity.....	114
4.4	Discussion	121
4.4.1	Kinetics of ponatinib resistance development in the <u>K562 T315I-R</u> cell line.....	121
4.4.2	Increased proportion of the T315I mutation reduced ponatinib efficacy in the <u>K562 T315I-R</u> cell line.....	122
4.4.3	Increase <i>BCR-ABL1</i> transcript expression mediates ponatinib resistance in the <u>K562 T315I-R</u> cell line.....	124
4.4.4	Summary	127

Chapter 5 :	128
5.1 Introduction	129
5.1.1 Compound mutation in Bcr-Abl kinase domain	129
5.1.2 ABCB1 overexpression	131
5.1.3 The <u>K562 DOX 55D</u> cell line	132
5.2 Approach	133
5.2.1 Generation of ponatinib resistant cell lines	133
5.2.2 Analysis of ponatinib-resistant cell line	135
5.3 Results	137
5.3.1 <u>K562 DOX 55D</u> cells cultured in 200 nM ponatinib demonstrate resistance to TKIs <i>in vitro</i>	137
5.3.2 ABCB1 is transiently up-regulated in the intermediate stages of the <u>K562 DOX 55D</u> ponatinib resistant cell line	145
5.3.3 <u>K562 DOX 55D</u> ponatinib resistance-developing cell lines demonstrate transient <i>BCR-ABL1</i> mRNA overexpression	149
5.3.4 <u>K562 DOX 55D</u> ponatinib resistant line harbours compound mutation G250E and E255K	149
5.3.5 Undetectable or low level of compound mutation was observed in the <u>K562 DOX 55D</u> 1 μ M PON and 2 μ M PON resistant lines	153
5.3.6 <u>K562 DOX 55D</u> ponatinib re-escalated <u>K562 DOX 55D 1μM PON(2)</u> resistant line demonstrated increased percentage of mutations and <i>BCR-ABL1</i> mRNA overexpression	157
5.4 Discussion	164

5.4.1	<i>BCR-ABL1</i> overexpression and the emergence of KD mutations.....	164
5.4.2	The development of compound mutation G250E/E255K has a significant impact in refractory CML.....	166
5.4.3	The <i>in vitro</i> formation of compound mutation G250E/E255K in the <u>K562 DOX 55D</u> ponatinib resistance developing cell lines	167
5.4.4	Bcr-Abl independent resistance in the <u>K562 DOX 55D 1μM PON</u> cell line.....	171
5.4.5	Kinetics of ponatinib resistance development in the <u>K562 DOX 55D-R</u> cell line	171
5.4.6	Transient ABCB1 overexpression	172
5.4.7	Summary	174
Chapter 6	:	175
6.1	Introduction	176
6.1.1	Bcr-Abl independent resistance.....	176
6.1.2	<u>K562</u> , <u>K562 DOX</u> and <u>KU812</u> cell lines in the current study.....	177
6.2	Approach	178
6.2.1	Generation of ponatinib resistant cell lines	178
6.3	Results.....	179
6.3.1	<u>K562</u> and <u>K562 DOX</u> cells cultured in 200 nM ponatinib demonstrate resistance to TKIs <i>in vitro</i>	179
6.3.2	<u>K562</u> and <u>K562 DOX</u> ponatinib resistant cell lines do not harbour <i>BCR-ABL1</i> KD mutations.....	194
6.3.3	ABCB1 is up-regulated in the <u>K562-R</u> ponatinib resistant cell line.....	194

6.3.4	<u>K562 DOX-R</u> but not <u>K562-R</u> ponatinib resistant-developing cell lines demonstrate increased <i>BCR-ABL1</i> mRNA.....	199
6.3.5	<u>K562</u> and <u>K562 DOX</u> ponatinib resistant lines demonstrated increase cell adhesion.....	202
6.3.6	<u>K562-R</u> and <u>K562 DOX-R</u> ponatinib resistant lines demonstrates Axl overexpression.....	203
6.3.7	Axl inhibition in the <u>K562-R</u> , <u>K562 DOX-R</u> and <u>K562 DOX 55D 1μM PON</u> ponatinib resistant lines restores sensitivity to ponatinib	210
6.3.8	AXL knock-down in the <u>K562-R</u> and <u>K562 DOX-R</u> ponatinib resistant lines restores sensitivity to ponatinib.....	215
6.4	Discussion	224
6.4.1	Axl overexpression is critical for Bcr-Abl-independent ponatinib resistance.....	225
6.4.2	Axl overexpression mediates cell adhesion.....	226
6.4.3	ABCB1 overexpression.....	227
6.4.4	Kinetics of ponatinib resistance development in the TKI naïve cell line model.....	228
6.4.5	Summary.....	228
Chapter 7	:	229
7.1	Introduction	230
7.2	Major findings.....	231
7.2.1	ABCB1, ABCG2 and OCT-1 are not major ponatinib transporters	231

7.2.2 Bcr-Abl dependent resistance, such as <i>BCR-ABL1</i> over-expression or compound mutations, is more likely to develop in the TKI pre-treated setting.....	234
7.2.3 Bcr-Abl independent resistance, such as Axl over-expression, is more likely to develop in the TKI naïve setting.....	239
7.2.4 Ponatinib resistance is likely to confer insensitivity to all the other available TKIs.....	243
7.3 Future directions.....	247
7.4 Conclusion.....	248
Appendix	250
Publications and awards	263
Reference	267

Declaration

I, Liu Lu, certify that this work contains no material which has been accepted for the award of any other degree or diploma in my name, in any university or other tertiary institution and, to the best of my knowledge and belief, contains no material previously published or written by another person, except where due reference has been made in the text. In addition, I certify that no part of this work will, in the future, be used in a submission in my name, for any other degree or diploma in any university or other tertiary institution without the prior approval of the University of Adelaide and where applicable, any partner institution responsible for the joint-award of this degree.

I give consent to this copy of my thesis when deposited in the University Library, being made available for loan and photocopying, subject to the provisions of the Copyright Act 1968.

The author acknowledges that copyright of published works contained within this thesis resides with the copyright holder(s) of those works.

I also give permission for the digital version of my thesis to be made available on the web, via the University's digital research repository, the Library Search and also through web search engines, unless permission has been granted by the University to restrict access for a period of time.

Liu Lu

23rd November 2015

Acknowledgements

Doing a PhD has been the most challenging, frustrating but also rewarding experience. This thesis would not have been possible without the help of many people in many ways.

I sincerely thank my supervisors, Professor Deb White and Professor Tim Hughes, for their guidance and wonderful supervision in helping me in all the time of research and writing of this thesis. Deb, I am deeply grateful for having you, a wise and passionate scientist, as my principal supervisor. Throughout these four years, you not only made a large effort in helping me with my research (and you still talked to me even when I bugged you 30 times a day), but also gave me support and encouragements beyond a supervisor's duty. I feel lucky to have you as my mentor and you truly are the best supervisor I have ever met. I also want to express my significant gratitude to Tim, for your continuous support of my PhD study and for your patience, motivation, and immense knowledge. Your CML knowledge and clinician's perspective has been invaluable.

A special thank you to Verity, for your friendship and always willing to help me (in experiment, writing and taking care of Judy) even when you are in the middle of your work, and for sharing your incredible technical expertise. It is always nice to talk to you, doesn't matter if it is work-related or animal-related. Thanks must go to Tamara, who spent a large amount of time in helping me with my writing—

manuscript, abstracts, posters and most importantly thesis—this thesis could not have been completed without your help. I also thank Eva and Chung, for their research ideas, suggestions and always sending me the latest papers I need for my research.

To Jackie, I feel so lucky to have you as a colleague and as a good friend. Talking to you always calmed me down when I was stressed and worried and grumpy. You always do your best (although you always said the opposite way, i.e. I clearly remember you said ‘ask your supervisors and leave me alone’ for > 30 times) in helping me solve my problems and answer my questions. To Ben and Kartini, even we threw stress balls and toys to each other (mostly Ben), you two made it a pleasure to come to work. Plus, I must thank you two (and Jackie) for scanning/printing/ deciphering people’s hand writing for me. Thank you to all the past and present members of the Melissa White Lab/ Leukaemia Research Unit, for providing me with a great and supportive work environment, and technical assistance.

Heartfelt thanks go to my beloved family, mum and dad, who always encourage me, believed in me and love me unconditionally. Even though we are far away, talking to my families always brightens my day. Lastly, I wish to thank Hang, who has been so supportive through this journey. You took care of my life, you got excited about my

results, you comforted me, you listened to my practice talks, you checked my references and you even understand my research. You gave me the power to keep moving forward. Words cannot express how grateful I am to have you in my life especially in this tough period.

Abstract

The use of tyrosine kinase inhibitors (TKIs), which target Bcr-Abl, has become the first-line treatment for chronic myeloid leukemia (CML). However, TKI resistance remains a major impediment to successful treatment of CML. The novel third generation pan-Bcr-Abl TKI ponatinib has demonstrated efficacy in overcoming single *BCR-ABL1* kinase domain (KD) mutation based resistance including *BCR-ABL1*^{T315I}, which inhibits the binding of all other available TKIs. While intracellular transport of the first and second generation TKIs have been studied, little is known about the complex interactions between ponatinib and drug transporters. Additionally, clinically significant mechanisms that may result in resistance to ponatinib remain to be elucidated. In this study, we investigated the interaction of ponatinib with drug transporters, and emerging modes of ponatinib resistance in previously TKI-naïve and dasatinib resistant *BCR-ABL1+* cell lines.

This study examined the role of ABCB1, ABCG2 and OCT transporters in ponatinib efflux and influx, as these transporters have been previously implicated in the transport of other TKIs. Results demonstrated neither ABCB1 ABCG2 nor OCT-1, play major roles in ponatinib transport. In addition, data revealed that ponatinib transport is not ATP/temperature dependent, and therefore is most likely to be passive.

To investigate potential resistance mechanism(s), ponatinib resistance was generated by exposure to increasing concentrations of ponatinib in *BCR-ABL1*+ cell-lines that either priorly treated with a TKI (dasatinib) or naïve to all TKIs. Two resistant cell lines, previously resistant to dasatinib and then treated with ponatinib, demonstrated the emergence of *BCR-ABL1* KD mutation(s). In one of these cell lines, the level of T315I increased from 44% to 66%, with *BCR-ABL1* mRNA expression also increasing. In the second cell line the compound mutation G250E/E255K developed. In contrast, the TKI (imatinib, nilotinib and dasatinib) naïve ponatinib resistant cell lines did not demonstrate *BCR-ABL1* KD mutations. Conversely, both of these resistant lines developed Bcr-Abl-independent resistance via Axl overexpression. Axl, a receptor tyrosine kinase, has previously been associated with TKI resistance. My studies are the first to report it in association with ponatinib resistance. In agreement with the observation that Axl overexpression causes ponatinib resistance, ponatinib sensitivity was restored following Axl inhibition or shRNA-mediated-knockdown of Axl.

In conclusion, the studies outlined in this thesis reveal that unlike other TKIs, ponatinib is not transported by ABCB1, ABCG2 or OCT-1 and therefore patients are unlikely to be susceptible to resistance caused by deregulation of these transporters. Moreover, the study also identified that in the setting of prior TKI-exposure, Bcr-Abl dependent mechanisms, such as *BCR-ABL1* KD mutations and *BCR-ABL1* mRNA overexpression, are likely to cause ponatinib resistance. However, in the TKI-naïve setting, Bcr-Abl-independent modes of resistance develop preferentially, and Axl

presents as a key mediator of this resistance. While further studies are required, particularly in reference to Axl expression in patients being treated with ponatinib, these data may suggest that combination therapeutic approaches may be the most efficacious in the setting of up-front ponatinib use and subsequent development of resistance.

Abbreviations

µg – Microgram/s

µL – Microlitre/s

µM – Micromolar

7-AAD – 7-Aminoactinomycin D

¹⁴C – Carbon-14 radioactive isotope

ABC – ATP Binding Cassette

ALL – Acute Lymphoblastic Leukaemia

AP – Accelerated Phase

ATCC – American Type Tissue Culture Collection

ATP – Adenosine Triphosphate

BC – Blast Crisis

BCR-ABL1 – Breakpoint Cluster Region-Abelson 1 (mRNA)

Bcr-Abl – Breakpoint Cluster Region-Abelson (protein)

BSA – Bovine Serum Albumin

CCyR – Complete Cytogenetic Remission

cDNA – Complementary DNA

CHR – Complete Haematological Response

CML – Chronic Myeloid Leukaemia

CP – Chronic phase

CrkL – CT10 regulator of kinase-like Ct – Cycle Threshold

DAS – Dasatinib

DEPC – Diethylpyrocarbonate

DMSO – Dimethyl Sulphoxide

DNA – Deoxyribonucleic Acid

EDTA – Ethylenediaminetetraacetic Acid

FACS – Fluorescence Activated Cell Sorting

FCS – Foetal Calf Serum

FDA – Food and Drug Administration

GUSB Beta-glucuronidase

x g – see rcf

h – Hour/s

HBSS – Hanks Balanced Salt Solution

IC50 – Inhibitory Concentration 50

IFN – Interferon

IgG –Immunoglobulin G

IUR – Intracellular Uptake and Retention

kDa – Kilo Daltons

KD – Kinase Domain

L – Litre/s

M - Molar

MDR – Multidrug Resistance Protein

MFI – Mean Fluorescence Intensity

mg – milligram/s

min – Minutes/s

mL – Millilitre/s

mM – Millimolar

MMR – Major Molecular Response

MNC/s – Mononuclear Cell/s

MQ – Milli-Q

mRNA – messenger RNA

MRP – Multidrug Resistance-Associated Protein

MW – Molecular Weight

ng – Nanogram/s

nM – Nanomolar

OCT-1 – Organic Cation Transporter 1

p – Phosphorylated Form of Protein

PAGE – Polyacrylamide Gel Electrophoresis

PB – Peripheral Blood PB

MNC/s – Peripheral Blood Mononuclear Cell/s

PBS – Phosphate Buffered Saline

PE – Phycoerythrin

P-gp – P-Glycoprotein

Ph – Philadelphia Chromosome

PON – Ponatinib

PSC – PSC-833

P value – Probability Value

PVDF – Polyvinylidene Difluoride

rcf – Relative Centrifugal Force

RNA – Ribonucleic Acid

RO – Reverse Osmosis

RQ-PCR – Real Time Quantitative PCR

SD – Standard Deviation

SDS – Sodium Dodecyl Sulphate

sec – second/s

SH1/SH2/SH3 – Src Homology Region 1/2/3

TBS – Tris Buffered Saline

TBST – Tris Buffered Saline +Tween[®]20

TKI/s – Tyrosine Kinase Inhibitor/s

TEA – Tetraethylammonium Bromide

U/mL – Units Per Millilitre